Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

What the paper reports

AstraZeneca chemists designed the first BET PROTACs explicitly for inhaled delivery, motivated by three PROTAC properties: inherent lung/skin tissue retention, catalytic “hit-and-run” mode of action, and reduced systemic toxicity potential Paper rationale and design hypothesis. Replacing H-bonding amide linkers with hydrophobic triazole/alkyne linkers yielded a >100-fold potency jump: compound 13 reached pDC50 9.72 (HEK293 HiBiT) and 0.29 nM BRD4 degradation in human lung fibroblasts, with full (100%) Dmax SAR tables and linker design.

Key in vivo finding

Neutral, low-solubility compound 13 (lung T½ ≈ 3.4 h as amorphous suspension) given intratracheally caused dose-dependent BRD4 loss throughout mouse lung—including alveoli—lasting 24 h after a single dose, with no effect in spleen. Critically, an equal intravenous dose produced no lung degradation, arguing the effect was locally delivered, not systemic spillover Mouse intratracheal vs intravenous degradation data. Compound 22's ester linker adds a soft-drug hydrolysis feature, and mouse CRBN Val380 explains species-dependent potency loss for basic analogues—a thoughtful species-difference analysis CRBN species-difference mechanistic explanation.

Critical assessment

• No efficacy model. Despite the IPF motivation, no bleomycin or fibrosis model was tested—BRD4 IHC degradation is a surrogate, not therapeutic proof. α-SMA inhibition was only in vitro.
• Mouse-only in vivo. All PK/efficacy is C57BL/6, n=2 for PK; species translation of CRBN-dependent degradation is a documented risk here by the authors' own analysis.
• Long-term safety unaddressed. Repeated dosing, local epithelial toxicity, systemic leakage with chronic dosing, and degradation-based immunosuppression risk (BET proteins in immune cells) are not assessed. BRD2 upregulation is a known adaptive resistance mechanism to BET inhibition BRD2 adaptive resistance to BET inhibition, and E3-ligase loss causes acquired PROTAC resistance PROTAC resistance via E3 ligase loss—both relevant to chronic inhaled dosing and unexamined.
• Conflict of interest. All authors are AstraZeneca employees with possible stock options; this is internal pipeline science, and only favorable data may be in the public record Conflict of interest statement.

Bottom line: a strong medicinal-chemistry proof-of-concept that opens a genuinely new design space (topical/inhaled degraders), but efficacy and safety claims remain untested. Confidence: moderate—chemistry and PK data are well-controlled; conclusions about therapeutic value are hypothesis-level.

 BGPT Paper Review

Study Novelty

First-described inhaled/topically administered BET PROTACs with demonstrated lung-restricted degradation sparing systemic tissues; no prior inhaled PROTAC examples exist in the field.

Scientific Quality

Well-controlled SAR, multi-assay in vitro profiling, PK, and mechanism-driven design; but no disease model, mouse-only in vivo, small PK n=2, and no safety/repeat-dose data. Industry-funded with full AZ employment conflicts, though disclosed.

Study Generality

Establishes transferable design principles (linker hydrophobicity, soft-drug esters, dissolution-driven lung retention) applicable to other inhaled degraders, but the validation is target-specific (BET/BRD4) and lung-specific.

Study Usefulness

Opens a new modality delivery route for degraders with clear design rules and validated in vivo local-restriction concept; highly useful for respiratory drug discovery despite missing efficacy proof.

Study Reproducibility

Full synthetic procedures, assay details, and ESI provided with stated confidences; but key in vivo data depend on proprietary compounds and IHC quantification details are not fully specified.

Explanatory Depth

Strong mechanistic reasoning: CRBN species-difference docking, hit-and-run kinetics, dissolution-driven retention; sustained BRD4 reduction attributed to slow resynthesis with SILAC support, though causation between local exposure and 24h effect is inferred, not proven.